SCHEMBL1834422

SCHEMBL1834422

OCCc1cc(F)cc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.39
GPR52 Q9Y2T5 2/20 0.37
METAP2 P50579 2/20 0.36
EPAS1 Q99814 2/20 0.36
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX5 P09917 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
BACE1 P56817 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.34
CA2 P00918 1/20 0.33
S100A9 P06702 1/20 0.33
MAPK14 Q16539 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
AURKA O14965 1/20 0.32
RPS6KB1 P23443 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16961664 0.88 EPAS1 (0.39) DAOGPR52METAP2EPAS1RAPGEF4
SCHEMBL2249765 0.84 TSHR (0.44) DAOTDP1KDM4EALDH1A1ALOX5
SCHEMBL1154666 0.84 IDO1 (0.42) DAOTDP1KDM4EALDH1A1ALOX5
SCHEMBL6026873 0.82 CYP4F2 (0.44) DAOMETAP2EPAS1RAPGEF4S100A9
SCHEMBL13349208 0.78 DAO (0.39) DAOMETAP2KDM4EALDH1A1GAA
SCHEMBL3237616 0.78 TAAR1 (0.50)
SCHEMBL16404716 0.78 DAO (0.36) DAOGPR52METAP2RAPGEF4S100A9
SCHEMBL13822389 0.78 DAO (0.36) DAOGPR52METAP2RAPGEF4S100A9
Hydrochloric Acid SCHEMBL12521203 0.77 TAAR1 (0.48)
SCHEMBL3930469 0.76 FFAR4 (0.47) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
US-8362049-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-01-29 US disclosed
US-8318778-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2012-11-27 US disclosed
US-20120165375-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2012-06-28 US disclosed
EP-2321287-A1 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
US-20100041711-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2010-02-18 US disclosed
WO-2010010014-A1 4,5-DIHYDRO-OXAZOL-2-YL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
EP-2099777-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2009-09-16 EP disclosed
WO-2008084044-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041711-A1 Urea Glucokinase Activators GCK, GCKR, HK2 DAO 1653/4885GPR52 2174/4885METAP2 581/4885
US-20120165375-A1 Urea Glucokinase Activators GCK, GCKR, HK2 DAO 1653/4885GPR52 2174/4885METAP2 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.